A novel improved therapy strategy for diabetic nephropathy
- 1 January 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Organogenesis
- Vol. 8 (1), 18-21
- https://doi.org/10.4161/org.19332
Abstract
Diabetic nephropathy (DN), is a disorder that causes significant morbidity and mortality. Studies on the pathological mechanisms of DN reveal that advanced glycation end products (AGEs) play an important role in the pathogenesis of DN through interacting with receptors for advanced glycation end products (RAGE), which activate a series of intracellular signaling pathways. AGEs and RAGE have therefore been considered to be two potential key targets. Although multiple studies have been made for anti-DN therapy against AGEs or RAGE, the results have been disappointing due to poor effectiveness or to side effects in clinical practice. In this hypothesis article, we propose a novel treatment based on a dual-target approach. A kind of multi-functional intelligent nanoparticle is constructed, which has a core-shell nanoparticle structure to load the dual-target drugs (AGEs inhibitors and RAGE inhibitors), and has a functional “RAGE analog” to be used as “bait” to catch AGEs and target them to the kidney. Owing to its advantages of having a dual-target, synergistic effect and high efficiency, the proposition may have potential applications in DN therapy.Keywords
This publication has 36 references indexed in Scilit:
- Advanced glycation end-products: Implications for diabetic and non-diabetic nephropathiesDiabetes & Metabolism, 2010
- Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expressionPharmacological Research, 2010
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expressionBiochemical and Biophysical Research Communications, 2010
- Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directionsPharmacological Research, 2009
- Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activationBiochemical and Biophysical Research Communications, 2009
- Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetesKidney International, 2007
- Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetesCardiovascular Diabetology, 2007
- Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetesDiabetologia, 2006
- Agents in development for the treatment of diabetic nephropathyExpert Opinion on Investigational Drugs, 2005
- Multilayer Assemblies of Silica-Encapsulated Gold Nanoparticles on Decomposable Colloid TemplatesAdvanced Materials, 2001